Synergy reports positive Phase III trial results of plecanatide in CIC patients
The trial evaluated the efficacy and safety of two different plecanatide treatment doses (3mg and 6mg), taken as a tablet once-a-day, in 1337 adults with CIC. According to
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.